Moreover, the finding that BCMA is expressed at similar levels during the various stages of MM, from previously untreated to relapse, suggests that BCMA may be a valid therapeutic target throughout the course of the disease [28]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.